Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PPE3-SEA
- Development stage
- Preclinical
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intratumoral
01
Overview
PPE3-SEA is an engineered oncolytic adenovirus designed to express the superantigen Staphylococcus enterotoxin A (SEA). Its tumor specificity is enhanced by the regulation of its E1A and E1B genes by the telomerase reverse transcriptase and hypoxia-inducible factor promoters, respectively. This design allows PPE3-SEA to induce cytopathic effects in tumor cells and recruit CD3+ T cells, leading to anti-tumor activity, as demonstrated in mouse models of bladder cancer.
02
Targets
MHC II (Major histocompatibility complex class II receptor)γδ TCR (T-cell receptor)
Beyond the preview
Go deeper on PPE3-SEA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PPE3-SEA.